Skip to main content
. 2017 Sep 20;8:1169. doi: 10.3389/fimmu.2017.01169

Figure 1.

Figure 1

Delayed CTLA4-Ig prevented acute rejection in C57BL/6 WT and μMT recipients. (A) Experimental design. (B) WT or (C) μMT recipients were transplanted with BALB/c donor hearts and received no treatment (No Rx), or CTLA4-Ig given twice a week starting on D0 (CLTA4-Ig D0+) or on D6 (CLTA4-Ig D6+), or isotype Ig starting on D6, for up to 30 days. Graft survival was monitored for 30 days.